ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Development Of A Glucagon-Like Peptide (GLP)-1 Intranasal Formulation
In vitro and in vivo results with a proprietary intranasal
formulation of GLP-1 were presented. GLP-1 is an incretin hormone
that has been demonstrated to lower blood glucose in patients with
diabetes. GLP-1 has also been shown to induce satiety and promote
weight loss. This evidence suggests that GLP-1 may have the
potential to be an agent for treating type 2 diabetes as well as
obesity.
Utilizing Nastech's intranasal drug delivery technology an intranasal
formulation of GLP-1 was developed that exhibited high cell viability
with increased permeation in vitro.
In vivo pharmacokinetic testing
with Nastech's formulation resulted in an 11 percent bioavailability
of the drug in a preclinical model demonstrating the ability to
significantly enhance delivery across the nasal epithelium.
Additionally, in vivo pharmacodynamic testing of the effect of the
drug on the body was conducted following intranasal administration of
GLP-1 or a subcutaneous injection of a proprietary formulation of
exendin-4.
The results showed that intranasal GLP-1 decreased peak
glucose concentration in a similar manner to exendin-4 and is
responsible for the release of insulin in response to elevated blood
glucose following an oral glucose tolerance test. We believe this
data supports the potential for further development of intranasal GLP-
1 as a treatment for type 2 diabetes.
The abstract is available at http://www.nastech.com.
Additionally, Paul Johnson, Ph.D., Chief Scientific Officer of
Nastech, participated in the AAPS Symposium, "Running Interference:
RNAi Therapeutics Enter the Clinic," discussing the challenges of
developing siRNA therapeutics to treat pandemic
influenza.
"We are pleased to share Nastech's research in discovering novel ways
to enhance intranasal drug delivery of peptides and proteins with the
outstanding group of scientists that gather annually at the
prestigious AAPS Biotechnology Conference," stated Paul Johnson,
Ph.D., Chief Scientific Officer of Nastech. "Additionally, Nastech's
participation in the symposium on siRNA therapeutics provided an
opportunity to discuss the exciting opportunities and challenges in
developing this new class of therapeutics with others in the
field."
About Nastech
Nastech is a pharmaceutical company developing innovative products
based on proprietary molecular biology-based drug delivery
technologies. Nastech and its collaboration partners are developing
products for multiple therapeutic areas including diabetes,
respiratory disease, inflammatory conditions, obesity and
osteoporosis. Additional information about Nastech is available at
http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking
statements within the meaning of Federal Securities laws that are
subject to certain risks and uncertainties and involve factors that
may cause actual results to differ materially from those projected or
suggested. Factors that could cause actual results to differ
materially from those in forward-looking statements include, but are
not limited to: (i) the ability of Nastech to obtain additional
funding; (ii) the ability of Nastech to attract and/or maintain
manufacturing, research, development and commercialization partners;
(iii) Nastech's and/or a partner's ability to successfully complete
product research and development, including preclinical and clinical
studies and commercialization; (iv) Nastech's and/or a partner's
ability to obtain required governmental approvals; and (v) Nastech's
and/or a partner's ability to develop and commercialize products that
can compete favorably with those of competitors. Additional factors
that could cause actual results to differ materially from those
projected or suggested in any forward-looking statements are
contained in Nastech's most recent periodic reports on Form 10-K and
Form 10-Q that are filed with the Securities and Exchange Commission.
Nastech assumes no obligation to update and supplement forward-
looking statements because of subsequent events.
http://www.nastech.com
Dezvoltarea unei Glucagon-Ca peptida (BPL) -1 Intranasal Formularea - Development Of A Glucagon-Like Peptide (GLP)-1 Intranasal Formulation - articole medicale engleza - startsanatate